Canaccord Genuity Group Forecasts Strong Price Appreciation for Apogee Therapeutics (NASDAQ:APGE) Stock

Apogee Therapeutics (NASDAQ:APGE) had its target price upped by equities researchers at Canaccord Genuity Group from $89.00 to $130.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group’s target price points to a potential upside of 75.53% from the stock’s previous close.

APGE has been the topic of a number of other research reports. Wolfe Research assumed coverage on Apogee Therapeutics in a report on Wednesday, January 7th. They issued a “peer perform” rating on the stock. Wall Street Zen lowered Apogee Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. UBS Group raised shares of Apogee Therapeutics to a “strong-buy” rating in a report on Wednesday, January 7th. Guggenheim raised their price target on shares of Apogee Therapeutics from $130.00 to $160.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Apogee Therapeutics in a report on Wednesday, January 21st. Three equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Apogee Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $109.31.

Apogee Therapeutics Stock Down 6.5%

Apogee Therapeutics stock traded down $5.18 during mid-day trading on Tuesday, hitting $74.06. 344,728 shares of the stock were exchanged, compared to its average volume of 1,014,072. The stock has a market capitalization of $5.15 billion, a price-to-earnings ratio of -17.48 and a beta of 1.39. Apogee Therapeutics has a 12 month low of $26.20 and a 12 month high of $84.56. The firm’s fifty day simple moving average is $71.28 and its two-hundred day simple moving average is $63.70.

Apogee Therapeutics (NASDAQ:APGE) last released its quarterly earnings data on Monday, March 2nd. The company reported ($1.03) earnings per share for the quarter, beating the consensus estimate of ($1.05) by $0.02. As a group, analysts forecast that Apogee Therapeutics will post -3.09 earnings per share for the current fiscal year.

Insider Buying and Selling at Apogee Therapeutics

In other news, CEO Michael Thomas Henderson sold 20,000 shares of the stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $74.78, for a total transaction of $1,495,600.00. Following the completion of the transaction, the chief executive officer owned 1,152,987 shares in the company, valued at approximately $86,220,367.86. This represents a 1.71% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Fairmount Funds Management Llc sold 1,750,000 shares of the company’s stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $76.30, for a total transaction of $133,525,000.00. Following the sale, the director directly owned 298,647 shares in the company, valued at approximately $22,786,766.10. This trade represents a 85.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 1,839,700 shares of company stock worth $140,118,083 over the last three months. 42.77% of the stock is currently owned by insiders.

Institutional Trading of Apogee Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Apogee Therapeutics by 2.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,529 shares of the company’s stock worth $921,000 after buying an additional 694 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of Apogee Therapeutics by 100.0% in the 1st quarter. Millennium Management LLC now owns 260,335 shares of the company’s stock worth $9,726,000 after purchasing an additional 130,164 shares in the last quarter. Creative Planning bought a new position in shares of Apogee Therapeutics during the 2nd quarter valued at about $392,000. Handelsbanken Fonder AB grew its position in Apogee Therapeutics by 13.3% during the second quarter. Handelsbanken Fonder AB now owns 8,500 shares of the company’s stock valued at $369,000 after acquiring an additional 1,000 shares during the last quarter. Finally, Legal & General Group Plc raised its position in Apogee Therapeutics by 7.4% in the 2nd quarter. Legal & General Group Plc now owns 27,689 shares of the company’s stock worth $1,203,000 after purchasing an additional 1,907 shares during the period. 79.04% of the stock is currently owned by institutional investors.

Trending Headlines about Apogee Therapeutics

Here are the key news stories impacting Apogee Therapeutics this week:

• Positive Sentiment: Positive Phase 2 APEX Part A 52‑week data showed durable maintenance and deepening of responses with both every‑3‑month and every‑6‑month dosing (EASI‑75 maintenance 75% and 85%; vIGA 0/1 maintenance 86% and 78%), supporting zumilokibart’s competitive profile and low‑frequency dosing advantage. GlobeNewswire release Benzinga summary
• Positive Sentiment: Brokerage support: Guggenheim raised its price target to $160 with a Buy rating (large upside vs. prior levels), and BTIG reaffirmed Buy with a $137 target — analyst optimism amplifies the clinical news and can attract momentum flows. Benzinga
• Positive Sentiment: Investor research and coverage: Seeking Alpha pieces and the conference call/transcript/slideshow provide deeper reads that highlight Zumilokibart’s infrequent‑dosing commercial case and the company’s cash runway, supporting buy arguments for longer‑term upside. Seeking Alpha analysis Conference call transcript/slideshow
• Neutral Sentiment: Short interest reporting is noisy/zero in the feed and shows no clear short‑position pressure; likely not a material driver today. (Data appears inconsistent.)
• Neutral Sentiment: Valuation discussion: independent writeups examine APGE’s valuation after recent moves — useful for framing risk/reward but not new company fundamentals. Valuation article
• Negative Sentiment: Planned $300M underwritten public offering announced — while proceeds boost cash runway and fund development, the offering is dilutive and can apply downward pressure on the share price until completed. GlobeNewswire offering notice
• Negative Sentiment: Some analyst valuation work (DCF) suggests intrinsic value nearer to ~$73/share, implying limited near‑term upside absent M&A or further positive catalysts — a caution for investors who view the post‑data market cap as elevated. Seeking Alpha valuation note

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.